Phase II Study of AK112 (Anti-PD-1 and VEGF Bi-specific Antibody) in the Treatment of Advanced Gynecological Carcinoma
Latest Information Update: 13 Oct 2022
At a glance
- Drugs Ivonescimab (Primary)
- Indications Carcinoma; Gynaecological cancer
- Focus Therapeutic Use
- Sponsors Akeso Biopharma
- 08 Oct 2022 Status changed from recruiting to active, no longer recruiting.
- 06 May 2021 New trial record